Graviton Bioscience Announces Strategic Investment from Sanofi to Advance Development of the Next Generation of Selective ROCK2 Inhibitors

Posted on by

Sanofi to make a strategic equity investment in Graviton Bioscience Corporation Sanofi to receive a 12-month right of first negotiation (ROFN) to explore collaboration opportunities spanning multiple indications, including immunological and metabolic syndrome indications NEW YORK, Feb. 1,…

Posted in UncategorizedTagged
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.